BCTX BriaCell Therapeutics Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1610820 · Fiscal year ends 07/31
Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-32.7%
TTM EPS YoY88.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-203.6%
ROA-154.3%
ROIC (approx.)-408.8%
Asset turnover—
Leverage & solvency
Liabilities / assets34.0%
Debt / equity0.00x
Current ratio2.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q4*2026-07-31 | 2026Q32026-04-30 | 2026Q22026-01-31 | 2026Q12025-10-31 | 2025Q4*2025-07-31 | 2025Q32025-04-30 | 2025Q22025-01-31 | 2025Q12024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $10.53M | $5.97M | $6.05M | $6.68M | $7.11M | $4.81M | $5.68M | $3.67M |
| SG&A expense | $2.05M | $1.65M | $1.48M | $1.64M | $1.44M | $1.52M | $1.48M | $1.49M |
| Operating income | -$12.58M | -$7.62M | -$7.53M | -$8.32M | -$8.55M | -$6.33M | -$7.17M | -$5.15M |
| Interest expense | $0 | $29,631 | — | — | $0 | $36,979 | — | — |
| Net income | -$12.32M | -$7.16M | -$7.22M | -$8.20M | -$8.09M | -$6.13M | -$6.29M | -$5.80M |
| EBITDA | -$12.55M | -$7.59M | -$7.51M | -$8.30M | -$8.54M | -$6.31M | -$7.14M | -$5.13M |
| EPS (basic) | — | -0.99 | -2.58 | -4.35 | — | -16.42 | -23.31 | -32.67 |
| EPS (diluted) | — | -0.99 | -2.58 | -4.35 | — | -16.42 | -23.31 | -32.67 |
| Weighted avg. shares (diluted) | — | 7.25M | 2.80M | 1.88M | — | 373,067 | 269,957 | 177,606 |
| Balance sheet | ||||||||
| Cash & equivalents | $9.85M | $6.88M | $29.90M | $2.71M | $10.49M | $12.46M | $5.01M | $5.79M |
| Short-term investments | $10.69M | $15.92M | — | $7.46M | $7.37M | — | — | — |
| Current assets | $22.04M | $25.39M | $32.18M | $11.35M | $19.93M | $14.79M | $7.16M | $8.22M |
| PP&E, net | $319,804 | $348,997 | $251,141 | $273,980 | $296,819 | $319,658 | $342,497 | $365,336 |
| Intangibles | $169,254 | — | — | $180,707 | $184,525 | $188,343 | $192,160 | $195,978 |
| Total assets | $23.58M | $27.07M | $33.59M | $13.08M | $21.65M | $17.00M | $9.36M | $10.41M |
| Current liabilities | $7.98M | $3.59M | $3.19M | $3.32M | $3.98M | $4.33M | $5.23M | $4.99M |
| Total liabilities | $8.02M | $3.66M | $3.38M | $3.72M | $4.32M | $5.06M | $6.14M | $6.70M |
| Shareholders' equity | $16.40M | $24.06M | $30.92M | $9.98M | $17.88M | $12.42M | $3.60M | $4.04M |
| Shares outstanding | 8.71M | 7.25M | 7.25M | — | 1.88M | 6.56M | 294,694 | 36.18M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.96M | -$7.02M | -$7.97M | -$7.70M | -$8.13M | -$7.16M | -$5.92M | -$6.96M |
| Capital expenditure | $0 | — | — | — | — | — | — | — |
| Free cash flow | -$5.96M | — | — | — | — | — | — | — |
| Investing cash flow | $4.99M | -$16.00M | $7.28M | -$75,000 | -$7.39M | -$105,000 | -$75,000 | -$75,000 |
| Financing cash flow | $3.94M | $0 | — | — | $13.56M | $14.71M | $5.22M | $11.96M |
| Depreciation & amortization | $29,193 | $29,193 | $22,839 | $22,839 | $11,386 | $22,839 | $30,475 | $22,839 |
| Stock-based compensation | $117,529 | $432,207 | $285,856 | $294,686 | $0 | $224,815 | $285,093 | $266,971 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.